Cohance Lifesciences Ltd (COHANCE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Cohance Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
Revised Results Conference Call
Intimation · 04 Nov 2026, 1:07 am
Cohance Lifesciences Revises Q2 and H1 FY27 Earnings Conference Call Timing Cohance Lifesciences Limited has rescheduled its investor and analyst conference call to discuss Q2 and H1 FY27 unaudited financial results. The call is now set for 6th Nov'26 at 6:00 p.m. IST, advanced from the previously scheduled time of 6:30 p.m. IST. The company will announce its financial results earlier on the same day, followed by management discussion and an interactive Q&A session. Primary domestic dial-ins include +91 22 6280 1141 and +91 22 7115 8042, alongside international toll-free options.
Results Conference Call
Intimation · 06 Nov 2026, 6:30 pm
Cohance Lifesciences Schedules Q2 and H1FY27 Earnings Conference Call Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has scheduled an earnings conference call for investors and analysts on 6th Nov'26 at 6:30 PM IST. The management will discuss the company's unaudited financial results for the quarter and half-year ended 30th Sep'26 (Q2 and H1FY27), which are slated for release earlier that day. The call will begin with management commentary followed by an interactive Q&A session. Primary domestic dial-in numbers include +91 22 6280 1141 and +91 22 7115 8042.
Cohance Lifesciences Limited has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 06 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 06 Nov 2026, 5:30 am
Cohance Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 06 Nov 2026, 5:30 am
Cohance Lifesciences Schedules Board Meeting on 6th Nov'26 for Q2/H1 Results Cohance Lifesciences Limited has scheduled its Board of Directors meeting for 6th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in the company's securities, which has been closed for designated persons and their immediate relatives since 28th Sep'26, will remain shut until 9th Nov'26.
General updates
Others (Uncategorized) · 13 Oct 2026, 1:21 am
Cohance Lifesciences Receives MCA Approval for Umang Vohra as Chairman and Group CEO Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) received Central Government approval from the Ministry of Corporate Affairs on 12th Oct'26 (via letter dated 8th Oct'26) for the appointment of Mr. Umang Vohra as Chairman and Group CEO. This regulatory clearance follows the company's prior intimations dated 27th Apr'26 and 26th Jun'26, formalizing the top leadership transition.
Appointment of Mr. Abhimanyu Ojha as Chief Financial Officer of the Company
Change in Management · 10 Oct 2026, 1:54 am
Cohance Lifesciences Appoints Abhimanyu Ojha as Chief Financial Officer Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has approved the appointment of Abhimanyu Ojha as Chief Financial Officer and Key Managerial Personnel, effective 12th Oct'26. Ojha brings over two decades of pharma and healthcare leadership experience, having previously served as Global CFO & President Finance at Intas Pharmaceuticals, along with senior leadership roles at Viatris, Sun Pharmaceuticals, and Ranbaxy Laboratories. He will also join the authorized Key Managerial Personnel panel alongside Chairman & Group CEO Umang Vohra to determine and disclose material events.
ESG Rating by Crisil ESG ratings & Analytics Limited
Others (Uncategorized) · 06 Oct 2026, 8:54 pm
Crisil Assigns Strong ESG Ratings to Cohance Lifesciences Crisil ESG Ratings & Analytics Limited has voluntarily assigned an ESG rating of "Crisil ESG 61 (Strong)" and a Core ESG rating of "Crisil Core ESG 67 (Strong)" to Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) on 6th Oct'26. The ratings were independently evaluated based on publicly available information, with no formal engagement initiated by the company.
General update
Others (Uncategorized) · 21 Sept 2026, 5:07 pm
Cohance Lifesciences Receives Five USFDA Form 483 Observations for Jaggaiahpet API Facility The USFDA completed an inspection of Cohance Lifesciences Limited's API manufacturing facility in Jaggaiahpet, Andhra Pradesh, conducted between 14th Sep'26 and 19th Sep'26. The audit concluded with the issuance of a Form FDA 483 with five observations. In response, the company has initiated corrective and preventive actions (CAPA) and plans to submit its formal response to the regulator within the stipulated timeline.
General update
Others (Uncategorized) · 19 Sept 2026, 12:04 am
Cohance Lifesciences Invests USD 10 Million in Subsidiary NJ Bio Cohance Lifesciences has remitted USD 10 million via internal accruals to subscribe to 188,680 Compulsorily Convertible Preferred Stocks (CCPS) of its US-based subsidiary, NJ Bio Inc., at USD 53.00 per share. The CCPS are convertible into equity after 3 years, with completion expected before the end of Sep'26. The capital infusion will fund growth initiatives and capex in NJ Bio's antibody-drug conjugate (ADC) CRDMO business. NJ Bio posted revenues of USD 20.6 million in CY23, USD 32.6 million in CY24, and USD 23.5 million in CY25.
Scrutinizer`s report
Annual General Meeting · 18 Sept 2026, 1:29 am
Cohance Lifesciences Shareholders Approve All Resolutions at 8th AGM Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced the successful passage of all ordinary resolutions at its 8th AGM held on 17th Sep'26. Shareholders approved the standalone and consolidated financial statements for FY25-26 with 99.9992% majority votes in favour. Additionally, the reappointment of Ms. Shweta Jalan as a director liable to retire by rotation was approved with 99.9731% voting in favour. Total voter turnout stood at 82.8877% of outstanding shares (317.13m votes polled out of 382.60m shares).
Proceedings of Annual General Meeting
Annual General Meeting · 18 Sept 2026, 1:26 am
Investor Meet
Intimation · 17 Sept 2026, 6:30 pm
Cohance Lifesciences Schedules Investor Interactions with JP Morgan Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its management will participate in upcoming investor conferences hosted by JP Morgan. The schedule includes the JP Morgan India Conference in Mumbai on 22nd Sep'26 for group and one-on-one meetings, followed by the JP Morgan Roadshow in Hyderabad on 24th Sep'26 for group interactions. The company confirmed that no unpublished price-sensitive information will be shared during these interactions.
Completion of USFDA Inspection
Others (Uncategorized) · 05 Sept 2026, 5:59 am
USFDA Concludes Inspection at Cohance Lifesciences Formulation Facility with Four Observations The USFDA completed an inspection of Cohance Lifesciences Limited's formulation (FDF) plant located at Shamshabad, Telangana, conducted from 27th Aug'26 to 4th Sep'26. The regulatory audit concluded with the issuance of a Form FDA 483 containing four observations. The company confirmed it has initiated appropriate corrective and preventive actions (CAPA) and will submit its formal response to the regulatory agency within the stipulated timeline.
Press Release
Press Release · 04 Sept 2026, 1:40 am
Cohance Lifesciences Invests $18M in NJ Bio and Aruka Bio to Advance ADC Strategy Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) strategy, expecting completion by Sep'26. A $13M allocation increases Cohance's equity in NJ Bio from 56.0% to 67.3%, integrating NJ Bio's CRDMO services with Cohance's commercial manufacturing. The remaining $5M secures a controlling 65% stake in Aruka Bio, making the preclinical ADC developer a direct subsidiary. This reorganization distinctly separates NJ Bio's customer-facing commercial operations from Aruka's proprietary drug pipeline development, positioning Aruka for future licensing partnerships.
Outcome of Committee Meeting
Others (Uncategorized) · 04 Sept 2026, 1:23 am
Cohance Lifesciences Advances ADC Strategy with $18M Investment in NJ Bio and Aruka Bio Cohance Lifesciences will invest $18M via internal accruals to strengthen its Antibody-Drug Conjugate (ADC) capabilities. Closing by Sep'26, the deal includes a $13M outlay for 244,587 additional shares of NJ Bio at $53/share, raising Cohance's stake from 56% to 67.3%. Concurrently, Cohance will invest $5M for a 65% controlling stake in Aruka Bio, a preclinical ADC platform. The reorganization integrates NJ Bio's CRDMO services with Cohance's manufacturing, while accelerating Aruka's proprietary pipeline. Dr. Naresh Jain will serve as CEO for both subsidiaries to drive commercial alignment.
Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026.
Others (Uncategorized) · 04 Sept 2026, 1:20 am
Investors Meet
Intimation · 27 Aug 2026, 10:52 pm
Cohance Lifesciences Management to Attend Investor Conference Cohance Lifesciences management will participate in the Ashwamedh - Elara India Dialogue 2026 conference in Mumbai on 1st Sep'26. The company will conduct group and one-on-one meetings with analysts and institutional investors. Cohance has confirmed that no unpublished price-sensitive information will be disclosed during these interactions. The schedule remains subject to change.
BRSR
Others (Uncategorized) · 27 Aug 2026, 1:45 am
Cohance Lifesciences FY26 BRSR: ESG Progress, Capex, and Key Financial Metrics For FY26, exports contributed 84% of turnover from manufacturing pharmaceuticals and chemicals, which accounted for 95.72% of total turnover. The company spent ₹23.19 Cr (1.12% of revenue) on employee wellbeing. Permanent employee turnover was 17%, and permanent worker turnover was 16.5%. ESG targets include Net Zero by 2050, validated by SBTi. A compounding fee of ₹8,29,88,900 was paid to the RBI for a past violation by an erstwhile merged entity. 41% of capex and 44% of R&D was invested in environmental/social impact technologies.
Annual Report 2026
Others (Uncategorized) · 27 Aug 2026, 1:42 am
Notice of AGM 2026
Annual General Meeting · 27 Aug 2026, 1:14 am
Credit Rating
Others (Uncategorized) · 13 Aug 2026, 6:05 pm
CRISIL Withdraws Cohance Lifesciences Rating on Non-Cooperation, Citing Weaker Financials CRISIL, on 12 Aug'26, withdrew its credit rating on Cohance Lifesciences at the company's request, migrating it to 'CRISIL BB/Stable/CRISIL A4+ Issuer not cooperating'. This action followed a downgrade from 'CRISIL AA-/Positive/CRISIL A1+' due to inadequate information and lack of management cooperation. CRISIL noted weaker Q1 FY27 results, with a consolidated net loss of Rs 45.19 crore versus a profit of Rs 46.40 crore YoY. This was on lower income of Rs 434.51 crore. The company maintains its ratings from India Ratings.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd
Acquisition/ Disposal of Shares · 12 Aug 2026, 4:40 pm
DSP Mutual Fund Sells Stake in Cohance Lifesciences DSP Trustee, on behalf of its mutual fund and AIF schemes, sold 2,899,996 shares of Cohance Lifesciences in an open market transaction on Aug 07, '26. This sale represents 0.76% of the company's total share capital. Following the disposal, DSP's total holding in Cohance Lifesciences decreased from 16,397,069 shares (4.29% stake) to 13,497,073 shares (3.53% stake). The filing was made under SEBI's takeover regulations as the change in holding exceeded the prescribed threshold.
Earnings Call Transcript
Transcript · 11 Aug 2026, 10:39 pm
Cohance Q1FY27 Results Weighed by CDMO Phasing; Guides for H2 Recovery Cohance Lifesciences reported a weak Q1FY27, with revenue declining 23% YoY to INR4,223 million and adjusted EBITDA at INR92 million, a 2.2% margin. The performance was driven by shipment phasing in the high-margin Pharma CDMO business, which saw revenues fall 38.7% YoY, and a 34.7% YoY decline in Specialty Chemicals. Strong growth from Sapala (2.5x revenue growth) and resilient API performance provided a partial offset. Management expects sequential improvement from Q2FY27 and a return to YoY growth in H2, supported by restocking orders and new programs.
Con Call audio link
Audio / Video · 06 Aug 2026, 3:19 am
Cohance Lifesciences Posts Q1 FY27 Earnings Call Audio Recording Cohance Lifesciences (NSE: COHANCE) has uploaded the audio recording of its earnings conference call for the quarter ended 30 Jun'26. The call was held on 05 Aug'26, following the results intimation on 23 Jul'26. The recording is accessible on the company's website. This provides investors and analysts with direct access to management's discussion and outlook on the Q1 FY27 performance and business environment.